Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +1.90% 26.75p 26.50p 27.00p 26.50p 26.00p 26.00p 1,349,902 16:35:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 38.6 -1.0 0.0 - 122.42

Ekf Diagnostics Share Discussion Threads

Showing 1426 to 1449 of 1450 messages
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
DateSubjectAuthorDiscuss
07/11/2017
07:38
Some large volumes of late, so I assume we will see RNS's accordingly. I am confident that EKF will deliver on their outlook in terms of sales growth. Over the medium term, the following could see a big uplift in revenues from the US - "Medium-term growth opportunities from new registrations and customers: – Draft agreements in place with OEM partners in USA for DiaSpect Tm and Quo-Test A1c" New EKF product introduction at Medica (next week) - Article by CHRIS MIDDLETON 06/11/2017 Cardiff-based EDK Diagnostics is set to introduce a new product at Medica – “POC Connect” – a data management mobile app that enables the storage, access and transmission of haemoglobin results directly from EFK Diagnostic’s DiaSpect Tm haemoglobin analyzer to a smartphone via Bluetooth® technology. The POC Connect mobile app is the world’s first mobile data management solution for a reagent-free haemoglobin testing device. POC Connect is ideal for mobile health checks and anaemia screening in countries where environmental conditions may be challenging or where there may not be consistent internet availability. Katja Lemburg, Hematology Global Product Manager from EKF Diagnostics said, “Within developing countries, there is a growing demand for mobile data management solutions due to the lack of internet-based communications infrastructure and the by-passing of more traditional based middleware providers. “So this new development is an ideal solution where internet connections can be unreliable. Mobile health care services are on the increase so we hope to see our smartphone-based connectivity solution playing a part in this growing trend. “We’re looking forward to unveiling this world first at Medica this year.” Full article - https://tinyurl.com/product-introduction
wan
05/11/2017
07:35
An excellent article - Diagnosing Diabetes: The Value of HbA1c Testing ARTICLE Nov 03, 2017 | By Anna MacDonald, Editor for Technology Networks We spoke to EKF’s Gavin Jones to learn more about the current methods of diabetes diagnosis and monitoring, the advantages of HbA1C testing, and how testing may change in the future. Where do you see the future of diabetes diagnostics headed? There are a number of improvements in the use of HbA1c for the monitoring of diabetes currently being considered, recently CAP (College of American Pathologists) and NGSP (National Glycohemoglobin Standardization Program) agreed that they should tighten the criteria for the HbA1c survey to ±5% beginning in 2019. Currently the requirement is to meet ±6% to the reference method, this change will undoubtedly reduce the number of available HbA1c methods on the market and improve the quality of results of those that remain, leading to a more controlled and consistent testing environment. Whilst seen by some manufacturers as a challenging criteria to meet, this change can only be looked upon as a positive improvement to the accuracy and precision of HbA1c monitoring on an industry-wide scale. Point-of-care testing As POC HbA1c testing becomes more accepted, it will start to become a more viable option for the diagnosis of diabetes. There are already POC HbA1c methods that meet the same criteria for diagnosis as lab systems, and with the increased accuracy being imposed upon the industry, the argument for only allowing lab systems to be used for diagnosis is slipping away. The benefits of POC HbA1c measurement, both clinically and from a patient-engagement perspective, cannot be ignored. It is only a matter of time before this becomes the accepted method for diabetes diagnosis. Full story (a very worthwhile read) - https://tinyurl.com/point-of-care-testing
wan
02/11/2017
16:36
2nd November 2017 EKF Diagnostics, the global in vitro diagnostics company, announces that its Stanbio Chemistry Procalcitonin (PCT) LiquiColor® assay has been FDA cleared and validated for use on Beckman AU 480, 680 and 5800 clinical chemistry analyzers. EKF is pleased to confirm the immediate availability of a user defined application (UDA) for running this 10 minute test for bacterial infection and sepsis on these Beckman AU analyzers. https://tinyurl.com/EKF-Procalcitonin-Assay
wan
26/10/2017
07:31
Sober reading, but there is a lot of growth to be realised - 26th October 2017 Novo Nordisk warns diabetes costs threaten to overwhelm healthcare Pharma chief says annual bill could hit $1tn by 2045 Only about 6 per cent of all people with diabetes today were being so effectively treated as to avoid the risk of potentially life-threatening, late-stage complications. He added: “We are far from having identified all the people with diabetes and [got] all of them on treatment so we see that as ample opportunity for us to still grow.” Full story - https://www.ft.com/content/d640dfe8-b991-11e7-9bfb-4a9c83ffa852
wan
18/10/2017
10:35
MW...Sorry to learn that. HbA1c can be used as a diagnostic test for diabetes and as a screening test for people at high risk of diabetes. But it is also a very important test for people managing diabetes, as any reduction in HbA1c levels will have beneficial effects with regard to reducing the risk of developing complications (nerve damage, eye disease, kidney disease and heart disease). One thing that I have always thought regarding type 1 diabetes, is that should there be a medical breakthrough preventing individuals from having to inject insulin (and thereby not having to regularly check/test glucose levels), regular HbA1c testing is very likely to still be recommended.
wan
18/10/2017
10:10
wan your post accords with my own experience, fasting blood glucose was all right just when I was diagnosed but HbA1c was clearly abnormal as was the glucose tolerance test, though one can't extrapolate from n=1!
mw8156
18/10/2017
10:04
9degrees...Yes I did note that, however, 60% of the world's diabetic population is Asian, so despite the limitations of the study from a global perspective, the findings are still relevant. It's an unfortunate fact that Asians are far more likely to develop diabetes compared with people from white European backgrounds. China has the largest diabetic population in the world, followed by India, the US is a distant 3rd! Why are Asians at Higher Risk? Studies have shown that Asians are at higher risk of developing type 2 diabetes, when compared with people of European ancestry.1 Asians are more likely to develop the disease even at a lower BMI. This means that even though some Asian populations currently have a lower prevalence of overweight and obese individuals than populations in the West, they have a disproportionately high percentage of people with diabetes.1 Currently, 60% of the world’s diabetic population is Asian. hxxp://asiandiabetesprevention.org/what-is-diabetes/why-are-asians-higher-risk
wan
18/10/2017
10:04
Double post!
wan
18/10/2017
09:39
Wan - all people tested were Vietnamese - not a typical western diet and lifestyle I wonder if that makes a difference ??
9degrees
18/10/2017
07:32
I noted the following recently - October 06, 2017 HbA1c vs Fasting Plasma Glucose for Prediabetes, Diabetes Diagnosis Patients with undiagnosed diabetes screened via fasting plasma glucose (FPG) may remain undiagnosed vs patients screened via hemoglobin A1c (HbA1c) blood test, according to a study published in PLOS ONE. The investigators concluded that HbA1c testing has a higher sensitivity for identifying patients at risk for diabetes vs FPG, and therefore may have a greater impact on the diagnoses, cost, burden, and treatment of patients with diabetes. Full story - https://tinyurl.com/HbA1c-testing
wan
14/10/2017
06:07
Ortho Clinical, EKF Expand Access to Ketoacidosis Assay Oct 11, 2017 NEW YORK – Ortho Clinical Diagnostics and EKF Diagnostic today announced a deal to provide patients expanded access to EKF's beta-hydroxybutyrate assay for the diagnosis of ketoacidosis. Full story - https://tinyurl.com/ortho-clinical-ekf-diagnostics
wan
11/9/2017
07:01
Excellent progress still being made, and given the 'long' list of new product registrations being pursued (amongst other things), it would appear there is a lot more growth and progress to come!
wan
09/8/2017
18:08
charts still indicate more upside
sirshagalot
07/8/2017
10:35
zwanzigger reduced his holdings
9degrees
18/7/2017
11:34
Kestelmill - I agree re the acquisition de-focus. However, just to qualify that - the only failed acquisition (out of 8) was Selah. This failed because the management team was not experienced enough (and arguably the industry was not ready) to move into molecular diagnostics alongside traditional point of care diagnostics.
tawnyport
18/7/2017
11:29
I would hardly classify a new NED as a new team. Anyway, the crux here is that a new non-exec Chairman is in place and he is an experienced, focussed, and successful individual - he is the one who has given the company a new lease of life by concentrating on an exit-based trade sale strategy, one which the previous Chairman arguably was unable to consummate.
tawnyport
18/7/2017
11:15
So we have more than just one new team member, arguably a different team, and perhaps most importantly, a new focus.
wan
18/7/2017
10:56
Wan - Julian Baines has been there as CEO since the Company listed in 2010; Richard Evans has been COO/CFO (and previously just CFO) since 2011. Adam has been an NED since 2010 and Carl was appointed an NED earlier this year.
tawnyport
18/7/2017
10:36
Tawnyport...I suggest you check the RNS announcements then, along with the following EKF investor page - hxxps://www.ekfdiagnostics.com/investors-directors-advisors.html
wan
18/7/2017
10:17
Wan - the only new management team member is Chris Mills; he replaced David Evans (who was succeeded by Ron Zwanziger for a short period).
tawnyport
17/7/2017
15:25
Large volume today!
wan
06/7/2017
16:04
Kestlemill...No it's not the same management team you refer to. EKF have a new management team in place, it has been restructured, refocused and refinanced, hence the significant improvements that are now flowing through.
wan
06/7/2017
15:48
Don't want to rain on your parade Wan - things are on the up - but isn't this the same management team who bought Selah Genomics for USD 35.6M plus milestone payments then less than two years later gave it back to Selah for nothing and wrote down GBP 41M off EKF's balance sheet?
kestelmill
06/7/2017
14:55
It has taken a long time but finally things are moving in the right direction. Well done. Let's just hope that the cash being generated doen't burn a hole in the management's pockets so that are tempted to make another disastrous (American) acquisition.
interstellar
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20171214 05:57:35